title: Coxsackievirus A16 encephalitis during obinutuzumab therapy, Belgium, 2013.
authors.forename: Tom
authors.initials: T
authors.lastname: Eyckmans
authors.forename: Elke
authors.initials: E
authors.lastname: Wollants
authors.forename: Ann
authors.initials: A
authors.lastname: Janssens
authors.forename: Hélène
authors.initials: H
authors.lastname: Schoemans
authors.forename: Katrien
authors.initials: K
authors.lastname: Lagrou
authors.forename: Joost
authors.initials: J
authors.lastname: Wauters
authors.forename: Johan
authors.initials: J
authors.lastname: Maertens
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001530:Belgium; D018792:Encephalitis, Viral / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D004770:Enterovirus / Q000145:classification* / Q000235:genetics; D004769:Enterovirus Infections / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D016756:Immunoglobulins, Intravenous; C543332:obinutuzumab
keywords: Belgium; CD20 B-cell antigen; coxsackievirus; coxsackievirus A16; encephalitis; enterovirus; monoclonal antibody; obinutuzumab; viruses
references.citation: Antivir Ther. 2012;17(3):459-66
references.pmid: 22293148
references.citation: BMC Med. 2013 Apr 04;11:88
references.pmid: 23557513
references.citation: Expert Opin Biol Ther. 2013 May;13(5):803-11
references.pmid: 23560506
references.citation: J Infect. 2014 Jan;68 Suppl 1:S108-14
references.pmid: 24119825
references.citation: J Clin Microbiol. 2004 Mar;42(3):963-71
references.pmid: 15004039
references.citation: Hum Vaccin Immunother. 2014;10(2):360-7
references.pmid: 24231751
references.citation: Emerg Infect Dis. 2013 Aug;19(8):1345-7
references.pmid: 23880543
references.citation: N Engl J Med. 2014 Mar 20;370(12):1101-10
references.pmid: 24401022
references.citation: Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):106-11
references.pmid: 23276889